

Ref. No: 1679  
Date: 15/04/25  
Subject: New biologic and targeted medications - Gastroenterology

## REQUEST & RESPONSE

Q1. How many patients were treated in March 2025 (or latest available month) by the gastroenterology department with the following biologic drugs?

- Etrasimod - 0
- Filgotinib – 5
- Golimumab - 0
- Mirikizumab - 3
- Ozanimod - 0
- Risankizumab - 9
- Tofacitinib - 8
- Upadacitinib - 11
- Ustekinumab (Stelara) - 7
- Ustekinumab Biosimilar - 75
- Vedolizumab - 46

Q2. How many patients were treated in March 2025 (or latest available month) for Crohn's disease with the following biologic drugs?

- Golimumab - 0
- Risankizumab - 1
- Upadacitinib - 4
- Ustekinumab (Stelara) - 2
- Ustekinumab Biosimilar - 8
- Vedolizumab - 6